References
- Layne KA, Dargan PI, Archer JRH, et al. Gadolinium deposition and the potential for toxicological sequelae – a literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol. 2018;84(11):2522–2534.
- Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66(2):175–179.
- Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43(12):817–828.
- Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med. 2006;130(2):209–212.2.0.CO;2] [https://doi.org/16454565]
- Sadowski EA, Bennett LK, Chan MR, Wentland AL, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148–157.
- Medical Imaging Drugs Advisory Committee Meeting – Gadolinium Retention after Gadolinium Based Contrast Magnetic Resonance Imaging in Patients with Normal Renal Function. Briefing Document September 8, 2017. [cited 2019 Sep] https://www.fda.gov/media/107133/download.
- Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol. 2004;39(3):138–142.
- White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol. 2006;41(3):272–278.
- Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics. 2009;1(6):479–488.
- Xia D, Davis RL, Crawford JA, et al. Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol. 2010;51(10):1126–1136.
- Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology. 2015;276(1):228–232.
- Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270(3):834–841.
- Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology. 2015;275(3):803–809.
- Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49(10):685–690.
- Murata N, Gonzalez-Cuyar LF, Murata K, et al. Macrocyclic and other non-group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function. Invest Radiol. 2016;51(7):447–453.
- McDonald JS, McDonald RJ, Jentoft ME, et al. Intracranial gadolinium deposition following gadodiamide-enhanced magnetic resonance imaging in pediatric patients: a case-control study. JAMA Pediatr. 2017;171(7):705–707.
- McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275(3):772–782.
- McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology. 2017;285:161595.
- [Cited 2019 Sep]. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm.
- [Cited 2019 Sep]. https://www.gov.uk/drug-safety-update/gadolinium-containing-contrast-agents-removal-of-omniscan-and-iv-magnevist-restrictions-to-the-use-of-other-linear-agents.
- [Cited 2019 Sep]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/07/WC500231829.pdf.
- Roberts DR, Lindhorst SM, Welsh CT, et al. High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol. 2016;51(5):280–289.
- Gathings RM, Reddy R, Santa Cruz D, et al. Gadolinium-associated plaques: a new, distinctive clinical entity. JAMA Dermatol. 2015;151(3):316–319.
- Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26:807–815.
- Gulani V, Calamante F, Shellock FG, et al. International Society for Magnetic Resonance in M. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16(7):564–570.,
- Gadolinium Toxicity – The Lighthouse Project. [cited 2019 Sep]. https://gadoliniumtoxicity.com/.
- MRI-Gadolinium-Toxicity. [cited 2019 Sep]. https://groups.yahoo.com/neo/groups/MRI-Gadolinium-Toxicity.
- MRI Gadolinium Toxicity. [cited 2019 Sep]. https://www.facebook.com/gadoliniumtoxicity/.
- MRI Gadolinium Contrast Awareness. [cited 2019 Sep]. https://www.facebook.com/MRI-Gadolinium-Contrast-Awareness-438942453126630/.
- Semelka RC, Ramalho M, AlObaidy M, et al. Gadolinium in humans: a family of disorders. AJR Am J Roentgenol. 2016;207(2):229–233.
- The Washington Post - Chuck Norris claims his wife was poisoned during MRI scans, sues for $10 million. [cited 2019 Sep]. https://www.washingtonpost.com/news/to-your-health/wp/2017/11/08/chuck-norris-claims-his-wife-was-poisoned-during-mri-scans-sues-for-10-million/?utm_term=.b486020fe105.
- CBS news – ‘Chuck Norris says MRI chemical poisoned his wife’. [cited 2019 Sep] https://www.cbsnews.com/news/chuck-norris-says-mri-chemical-poisoned-his-wife/.
- Cutter Law – ‘Chuck and Gena Norris, announce filing of gadolinium lawsuit.’ [cited 2019 Sep]. https://cutterlaw.com/dangerous-drugs/gadolinium-toxicity/chuck-and-gena-norris-announce-filing-of-gadolinium-lawsuit/.
- McNamara C, Rahmani G. Gena Norris and gadolinium deposition disease-the impact of celebrity health disclosure on public awareness. Magn Reson Med. 2018;80(4):1277–1278.
- Leung N, Pittelkow MR, Lee CU, et al. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus. 2009;2(4):309–311.
- Miller JH, Hu HH, Pokorney A, Cornejo P, et al. MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics. 2015;136(6):e1637–e1640.
- Burke LM, Ramalho M, AlObaidy M, et al. Self-reported gadolinium toxicity: a survey of patients with chronic symptoms. Magn Reson Imaging. 2016;34(8):1078–1080.
- Semelka RC, Commander CW, Jay M, et al. Presumed gadolinium toxicity in subjects with normal renal function: a report of 4 cases. Invest Radiol. 2016;51(10):661–665.
- Semelka RC, Ramalho J, Vakharia A, et al. Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magn Reson Imaging. 2016;34(10):1383–1390.
- Semelka RC, Ramalho M, Jay M, et al. Intravenous calcium-/zinc-diethylene triamine penta-acetic acid in patients with presumed gadolinium deposition disease: a preliminary report on 25 patients. Invest Radiol. 2018;53(6):373–379.
- Greenberg SA. Zinc transmetallation and gadolinium retention after MR imaging: case report. Radiology. 2010;257(3):670–673.
- Conte G, Preda L, Cocorocchio E, et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol. 2017;27(10):4372.
- Khurana A, Greene JF, Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol. 2008;59(2):218–224.
- Christensen KN, Lee CU, Hanley MM, et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2011;64(1):91–96.
- Saussereau E, Lacroix C, Cattaneo A, et al. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int. 2008;176(1):54–57.
- Nowak S, Kunnemeyer J, Terborg L, et al. Analysis of whole blood samples with low gas flow inductively coupled plasma-optical emission spectrometry. Anal Bioanal Chem. 2015;407(3):1023–1026.
- Liang Q, Yin H, Li J, et al. Investigation of rare earth elements in urine and drinking water of children in mining area. Med (Baltimore). 2018;97(40):e12717.
- Mayo Medical Laboratories Gadolinium, Serum. [cited 2019 Sep]. https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/89299.
- Mayo Medical Laboratories Gadolinium, 24 Hour, Urine. [cited 2019 Sep]. https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/89301.
- United States Food & Drug Administration, Medical Imaging Drugs Advisory Committee Meeting briefing document (with Mayo Clinic reference ranges listed). [cited 2019 Sep]. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/medicalimagingdrugsadvisorycommittee/ucm572848.pdf.
- Choi SM. Movement disorders following cerebrovascular lesions in cerebellar circuits. JMD. 2016;9(2):80–88.
- Bond KM, Brinjikji W, Eckel LJ, et al. Dentate update: imaging features of entities that affect the dentate nucleus. AJNR Am J Neuroradiol. 2017;38(8):1467–1474.
- Radbruch A. Gadolinium deposition in the brain: we need to differentiate between chelated and dechelated gadolinium. Radiology. 2018;288(2):434–435.
- Wax PM. Current use of chelation in American health care. J Med Toxicol. 2013;9(4):303–307.
- Lohrke J, Frenzel T, Endrikat J, et al. 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives. Adv Ther. 2016;33(1):1–28.
- Khawaja AZ, Cassidy DB, Al Shakarchi J, et al. Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. Insights Imaging. 2015;6(5):553–558.
- Prybylski JP, Semelka RC, Jay M. Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy. Magn Reson Imaging. 2016;34(10):1391–1393.
- Bose C, Megyesi JK, Shah SV, et al. Evidence suggesting a role of iron in a mouse model of nephrogenic systemic fibrosis. PLoS One. 2015;10(8):e0136563.
- Boyken J, Frenzel T, Lohrke J, et al. Impact of treatment with chelating agents depends on the stability of administered GBCAs: a comparative study in rats. Invest Radiol. 2019;54(2):76–82.
- Cremin JD, Jr., Luck ML, Laughlin NK, et al. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. Toxicol Appl Pharmacol. 1999;161(3):283–293.
- Stangle DE, Strawderman MS, Smith D, et al. Reductions in blood lead overestimate reductions in brain lead following repeated succimer regimens in a rodent model of childhood lead exposure. Environ Health Perspect. 2004;112(3):302–308.
- Smith D, Strupp BJ. The scientific basis for chelation: animal studies and lead chelation. J Med Toxicol. 2013;9(4):326–338.
- Prybylski JP, Coste Sanchez C, Jay M. Impact of chelation timing on gadolinium deposition in rats after contrast administration. Magn Reson Imaging. 2019;55:140–144.
- Rees JA, Deblonde GJ, An DD, Ansoborlo C, et al. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents. Sci Rep. 2018;8(1):4419.
- Lyapustina T, Goldfine C, Rhyee S, et al. Evaluating the patient with reported gadolinium-associated illness. J Med Toxicol. 2019;15(1):36–44.
- Maximova N, Gregori M, Zennaro F, et al. Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology. 2016;281(2):418–426.
- Group AL. ALSUntangled update 2: investigating the hickey wellness center. Amyotroph Lateral Scler. 2009;10:490–491.
- Group AL. ALSUntangled: introducing the table of evidence. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:142–145.
- World Health Organisation – Europe. Health risks of heavy metals from long-range transboundary air pollution. [cited Sep 2019] http://www.euro.who.int/__data/assets/pdf_file/0007/78649/E91044.pdf.
- Saravanabhavan G, Werry K, Walker M, et al. Human biomonitoring reference values for metals and trace elements in blood and urine derived from the Canadian Health Measures Survey 2007-2013. Int J Hyg Environ Health. 2017;220(2):189–200.
- Flora SJ, Bhattacharya R, Vijayaraghavan R. Combined therapeutic potential of meso-2,3-dimercaptosuccinic acid and calcium disodium edetate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol. 1995;25(2):233–240.
- Berlin M, Jerksell LG, Nordberg G. Accelerated uptake of mercury by brain caused by 2,3-dimercaptopropanol (BAL) after injection into the mouse of a methylmercuric compound. Acta Pharmacol Toxicol (Copenh). 2009;23(4):312–320.
- Hoover TD, Aposhian HV. BAL increases the arsenic-74 content of rabbit brain. Toxicol Appl Pharmacol. 1983;70(1):160–162.
- Aposhian MM, Maiorino RM, Xu Z, Aposhian HV. Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rat. Toxicology. 1996;109(1):49–55.
- van Eijkeren JC, Olie JD, Bradberry SM, et al. Modeling the effect of succimer (DMSA; dimercaptosuccinic acid) chelation therapy in patients poisoned by lead. Clin Toxicol (Phila). 2017;55(2):133–141.
- Bradberry S, Vale A. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. Clin Toxicol (Phila). 2009;47(9):841–858.
- American College of Medical T. American College of Medical Toxicology position statement on post-chelator challenge urinary metal testing. J Med Toxicol. 2010;6:74–75.
- Brown MJ, Willis T, Omalu B, et al. Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005. Pediatrics. 2006;118(2):e534–e536.
- Risher JF, Amler SN. Mercury exposure: evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology. 2005;26(4):691–699.
- Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila). 2008;46(10):1083–1084.
- Wilson J, Gleghorn K, Seigel Q, et al. Nephrogenic systemic fibrosis: a 15-year retrospective study at a single tertiary care center. J Am Acad Dermatol. 2017;77(2):235–240.